Related Experiment Video
Updated: Mar 2, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells
Amani I Moraya1, Jennifer L Ali1, Pranati Samadder1
1Dept. of Biochemistry & Medical Genetics, University of Manitoba, Room 333 BMSB, 745 Bannatyne Avenue, Winnipeg, R3E 0 W9, MB, Canada.
Background:
Chemotherapy resistance is one of the major factors contributing to mortality from human epithelial ovarian cancer (EOC). Identifying drugs that can effectively kill chemotherapy-resistant EOC cells would be a major advance in reducing mortality. Glycosylated antitumour ether lipids (GAELs) are synthetic glycolipids that are cytotoxic to a wide range of cancer cells. They appear to induce cancer cell death in an apoptosis-independent manner.
Methods:
Herein, the effectiveness of two GAELs, GLN and MO-101, in killing chemotherapy-sensitive and -resistant EOC cells lines and primary cell samples was tested using monolayer, non-adherent aggregate, and non-adherent spheroid cultures.
Results:
Our results show that EOC cells exhibit a differential sensitivity to the GAELs. Strikingly, both GAELs are capable of inducing EOC cell death in chemotherapy-sensitive and -resistant cells grown as monolayer or non-adherent cultures. Mechanistic studies provide evidence that apoptotic-cell death (caspase activation) contributes to, but is not completely responsible for, GAEL-induced cell killing in the A2780-cp EOC cell line, but not primary EOC cell samples.
Conclusions:
Studies using primary EOC cell samples supports previously published work showing a GAEL-induced caspase-independent mechanism of death. GAELs hold promise for development as novel compounds to combat EOC mortality due to chemotherapy resistance.
Insights
Glycosylated antitumour ether lipids (GAELs) show promise in killing chemotherapy-resistant epithelial ovarian cancer (EOC) cells. These compounds induce cell death through both apoptosis-dependent and -independent pathways, offering a potential new strategy against EOC mortality.
Area of Science:
- Oncology
- Cancer Biology
- Drug Discovery
Background:
- Chemotherapy resistance is a primary driver of mortality in human epithelial ovarian cancer (EOC).
- Developing novel therapeutic agents to overcome chemoresistance is critical for improving patient outcomes.
- Glycosylated antitumour ether lipids (GAELs) are synthetic glycolipids with demonstrated cytotoxicity against various cancer cell types, potentially acting via apoptosis-independent mechanisms.
Purpose of the Study:
- To evaluate the efficacy of two GAELs, GLN and MO-101, against both chemotherapy-sensitive and -resistant EOC cell lines and primary samples.
- To investigate the cell death mechanisms induced by GAELs in different EOC culture models.
Main Methods:
- Testing GAEL effectiveness in monolayer, non-adherent aggregate, and non-adherent spheroid cultures.
- Utilizing chemotherapy-sensitive and -resistant EOC cell lines and primary patient-derived samples.
- Conducting mechanistic studies to elucidate the pathways of GAEL-induced cell death, including caspase activation.
Main Results:
- EOC cells displayed differential sensitivity to the tested GAELs.
- Both GLN and MO-101 effectively induced cell death in chemotherapy-sensitive and -resistant EOC cells across monolayer and non-adherent culture formats.
- Apoptotic cell death (caspase activation) was implicated in GAEL-induced killing in the A2780-cp EOC cell line but not in primary EOC samples.
Conclusions:
- GAELs demonstrate significant potential for combating EOC, particularly in cases of chemotherapy resistance.
- Mechanistic studies on primary EOC samples suggest a predominantly caspase-independent cell death pathway for GAELs, aligning with previous findings.
- GAELs represent a promising class of novel compounds for therapeutic development to reduce EOC-related mortality.
